1,011,863 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Bought by Contrarius Group Holdings Ltd

Contrarius Group Holdings Ltd acquired a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,011,863 shares of the company's stock, valued at approximately $11,798,000. Intellia Therapeutics accounts for approximately 0.7% of Contrarius Group Holdings Ltd's investment portfolio, making the stock its 25th largest holding. Contrarius Group Holdings Ltd owned 0.99% of Intellia Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Regeneron Pharmaceuticals Inc. bought a new position in shares of Intellia Therapeutics during the 4th quarter worth $43,177,000. State Street Corp lifted its holdings in Intellia Therapeutics by 17.9% during the third quarter. State Street Corp now owns 5,143,534 shares of the company's stock valued at $105,700,000 after purchasing an additional 780,754 shares during the last quarter. Raymond James Financial Inc. bought a new position in Intellia Therapeutics during the fourth quarter worth about $4,793,000. ARK Investment Management LLC boosted its position in Intellia Therapeutics by 2.3% during the fourth quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock worth $146,174,000 after purchasing an additional 280,946 shares during the period. Finally, Two Sigma Advisers LP increased its stake in shares of Intellia Therapeutics by 33.5% in the third quarter. Two Sigma Advisers LP now owns 1,027,617 shares of the company's stock worth $21,118,000 after purchasing an additional 257,700 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Transactions at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the firm's stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares of the company's stock, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last three months, insiders sold 29,000 shares of company stock worth $352,551. 3.20% of the stock is currently owned by corporate insiders.

Intellia Therapeutics Stock Performance

NTLA traded up $0.31 during trading on Monday, reaching $9.31. The stock had a trading volume of 2,522,784 shares, compared to its average volume of 2,115,457. The business has a 50-day moving average of $10.09 and a 200-day moving average of $14.13. Intellia Therapeutics, Inc. has a one year low of $8.30 and a one year high of $28.23. The stock has a market cap of $963.74 million, a PE ratio of -1.71 and a beta of 1.97.

Wall Street Analyst Weigh In

NTLA has been the topic of a number of recent research reports. Morgan Stanley cut shares of Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their price target for the company from $56.00 to $11.00 in a research note on Monday, January 27th. Oppenheimer cut their price target on Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a report on Monday, January 13th. BMO Capital Markets reduced their price target on Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating for the company in a research report on Friday, January 10th. StockNews.com raised Intellia Therapeutics to a "sell" rating in a report on Monday, March 3rd. Finally, Citigroup lifted their target price on Intellia Therapeutics from $12.00 to $14.00 and gave the company a "neutral" rating in a report on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $37.56.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.